WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

Dr Reddy's Laboratories Ltd reported a weaker-than-expected March quarter performance, weighed down by lower sales in North America and the impact of g-Revlimid-related adjustments. Brokerages largely ...

Analysts have raised concerns around Dr Reddy’s Laboratories’ growth outlook after the pharmaceutical company posted a weaker-than-expected March quarter (Q4FY26) result. They believe a sharp decline ...

Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the back of lower sales and multiple ...

Dr Reddy shares: Shares of pharma major Dr Reddy's Laboratories swung between gains and losses in morning deals on the BSE on Wednesday, 13 May, a day after reporting a 86% year-on-year (YoY) drop in ...

Hyderabad: Lower lenalidomide sales (Revlimid) in the North America markets dragged Dr Reddy’s Labs’ consolidated net profit by 86% for the fourth quarter ended March 31, 2026, to nearly Rs 221 crore ...

Dr Reddy's Laboratories Ltd on Tuesday reported a sharp decline in its consolidated net profit for the March-ended quarter, falling 86 per cent year-on-year (YoY) to Rs 221 crore compared with Rs ...

Dr Reddy's Q4 profit slumps 86% due to cancer therapy impairment Revenue falls 11.5% amid US pricing pressure and competition Lenalidomide sales drop; semaglutide eyed for future growth Drugmaker Dr ...

Sequentially, or on a quarter-on-quarter (QoQ) basis, Dr Reddy's profit fell nearly 82% from ₹1,209.8 crore in Q3FY26. The sharp decline in profit was impacted by a shelf stock adjustment related to ...

Good day, everyone and welcome to the Quarter 4 and Full Year FY '26 Earnings Call of Dr. Reddy's Laboratories Limited. I'm Aishwarya Sitharam, Head of Investor Relations of Dr. Reddy's. Joining us ...

Pharma major Dr Reddy’s Laboratories is likely to post a dip in its consolidated net profit at about ₹1,040 crore in the fourth quarter ended March 31, 2026 compared to ₹1,587 crore in the ...

Cipla, Dr. Reddy's and Tata Steel amongst major stocks to announce results this week (Image: AI-Generated) Pharma stocks would be in special focus on Tuesday, May 12, as Dr. Reddy’s Laboratories and ...